Visual Acuity Improvement of Amblyopia in an Adult With Levodopa/Carbidopa Treatment.
Amblyopia is the leading cause of visual loss in children, affecting 2% to 3% of the population. Occlusion of the dominant eye is the primary and best treatment, although efficacy decreases after 6 years of age. As a result, levodopa/carbidopa has been explored as an adjunct to conventional therapy and has been shown to have an immediate impact on visual acuity. Several studies to date have shown mixed results on the benefit of supplementing occlusion therapy with levodopa/carbidopa, although they have primarily studied children. The authors describe the oldest patient (46 years old) documented in the literature to have shown improvement in visual acuity using levodopa/carbidopa. He was given a 16-week course at a dose in line with previous studies while being effectively occluded full time due to a glaucomatous right eye with no light perception. On 3-month follow-up, his left eye improved two lines and stabilized at 6 months.
Faruk H
FH
Orge
Suhail A
SA
Dar
D000284:Administration, Oral; D000550:Amblyopia / Q000188:drug therapy* / Q000503:physiopathology; D002230:Carbidopa / Q000008:administration & dosage*; D015259:Dopamine Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D014792:Visual Acuity / Q000502:physiology*
D015259:Dopamine Agents; D007980:Levodopa; D002230:Carbidopa